Whitehawk Therapeutics, Inc. Share Price Today, Financials & AI Analysis — Stockinder

Jarvis is thinking

Whitehawk Therapeutics, Inc. Share Price Today, Financials & AI Analysis — Stockinder

Income Statement

	2025-12-31	2024-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	$7.14M	$25.98M
The direct costs of producing what was sold — raw materials, manufacturing, direct labor.	$760000	$3.02M
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$114.40M	-$67.46M
Operating income as a percentage of revenue.	-1601.1%	-259.6%
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$20.60M	-$63.70M
Net income divided by the number of shares outstanding — profit attributable to each share.	$0.00	$-2.00
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$0.00	$-2.00

Balance Sheet

	2025-12-31	2024-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$37.57M	$28.67M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$150.83M	$70.32M
Everything the company owes — debt, unpaid bills, and other obligations.	$14.52M	$17.84M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$136.31M	$52.48M

Cash Flow Statement

	2025-12-31	2024-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$97.43M	-$59.55M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$552000	$1.65M
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	-$97.98M	-$61.20M

Peer Comparison

	You	Peer avg
P/E	–	11.6
Revenue Growth	–	+27.1%
ROE	-45.0%	-34.4%